研究单位：[1]Shanghai Mental Health Center[2]Beijing Anding Hospital of Capital Medical University,Beijing 1816670,Beijing Municipality 2038349,China,100000[3]Renmin Hospital of Wuhan University,Wuhan 1791247,Hubei 1806949,China,430000[4]Nanjing Brain Hospital Affiliated to Nanjing Medical University,Nanjing 1799962,Jiangsu 1806260,China,210000[5]Dalian Seventh People''s Hospital,Dalian 1814087,Liaoning 2036115,China,116000[6]Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine,Shanghai 1796236,Shanghai Municipality 1796231,China,200030[7]First Affiliated Hospital of Kunming Medical University,Kunming 1804651,Yunnan 1785694,China,650000[8]Hangzhou Seventh People''s Hospital,Hangzhou 1808926,Zhejiang 1784764,China,310000
This study is a sequential multiple-assignment randomized trial (RCT) of antipsychotic medication treatment in first-episode schizophrenia patients in the real-world settings.Through analysis of treatment efficacy rate and adverse reactions and pharmacoeconomic evaluation, this project intends to provide evidence for the selection of antipsychotics in FES patients as well as the efficacy and safety of using clozapine in the early phase of schizophrenia treatment by comparing with other SGAs.
